Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Head and Neck Cancer

  Free Subscription


Articles published in Oral Oncol

Retrieve available abstracts of 214 articles:
HTML format
Text format



Single Articles


    May 2017
  1. CHOUGULE A, Patil VM, Noronha V, Joshi A, et al
    Incidence and impact of Dihydropyrimidine dehydrogenase gene mutation on neoadjuvant chemotherapy in head and neck cancers.
    Oral Oncol. 2017 May 22. pii: S1368-8375(17)30115.
    PubMed     Text format    


  2. SHAIKH MH, Clarke DTW, Johnson NW, McMillan NAJ, et al
    Can gene editing and silencing technologies play a role in the treatment of head and neck cancer?
    Oral Oncol. 2017;68:9-19.
    PubMed     Text format     Abstract available


  3. NOIJ DP, Martens RM, Marcus JT, de Bree R, et al
    Intravoxel incoherent motion magnetic resonance imaging in head and neck cancer: A systematic review of the diagnostic and prognostic value.
    Oral Oncol. 2017;68:81-91.
    PubMed     Text format     Abstract available


  4. ZHAI RP, Kong FF, Du CR, Hu CS, et al
    Radiation-induced hypothyroidism after IMRT for nasopharyngeal carcinoma: Clinical and dosimetric predictors in a prospective cohort study.
    Oral Oncol. 2017;68:44-49.
    PubMed     Text format     Abstract available


  5. HUANG TT, Huang JS, Wang YY, Chen KC, et al
    Novel quantitative analysis of autofluorescence images for oral cancer screening.
    Oral Oncol. 2017;68:20-26.
    PubMed     Text format     Abstract available


    April 2017
  6. RUEDA A, Giralt J, Manos M, Lozano A, et al
    Multidisciplinary management of head and neck cancer: First expert consensus using Delphi methodology from the Spanish Society for Head and Neck Cancer (part 2).
    Oral Oncol. 2017 Apr 17. pii: S1368-8375(17)30087.
    PubMed     Text format     Abstract available


  7. MANOS M, Giralt J, Rueda A, Cabrera J, et al
    Multidisciplinary management of head and neck cancer: First expert consensus using Delphi methodology from the Spanish Society for Head and Neck Cancer (part 1).
    Oral Oncol. 2017 Apr 17. pii: S1368-8375(17)30088.
    PubMed     Text format     Abstract available


  8. AYUBI E, Safiri S
    Lateral lymph node recurrence after total thyroidectomy and central neck dissection in patients with papillary thyroid cancer without clinical evidence of lateral neck metastasis: Comment on data sparsity.
    Oral Oncol. 2017 Apr 17. pii: S1368-8375(17)30086.
    PubMed     Text format    


  9. YANG Q, Zou X, You R, Liu YP, et al
    Proposal for a new risk classification system for nasopharyngeal carcinoma patients with post-radiation nasopharyngeal necrosis.
    Oral Oncol. 2017;67:83-88.
    PubMed     Text format     Abstract available


  10. BORCHIELLINI D, Etienne-Grimaldi MC, Bensadoun RJ, Benezery K, et al
    Candidate apoptotic and DNA repair gene approach confirms involvement of ERCC1, ERCC5, TP53 and MDM2 in radiation-induced toxicity in head and neck cancer.
    Oral Oncol. 2017;67:70-76.
    PubMed     Text format     Abstract available


  11. HANNA GJ, Liu H, Jones RE, Bacay AF, et al
    Defining an inflamed tumor immunophenotype in recurrent, metastatic squamous cell carcinoma of the head and neck.
    Oral Oncol. 2017;67:61-69.
    PubMed     Text format     Abstract available


  12. OUYANG PY, Zhang LN, Xiao Y, Lan XW, et al
    Validation of published nomograms and accordingly individualized induction chemotherapy in nasopharyngeal carcinoma.
    Oral Oncol. 2017;67:37-45.
    PubMed     Text format     Abstract available


  13. PEREZ CA, Wu X, Amsbaugh MJ, Gosain R, et al
    High-dose versus weekly cisplatin definitive chemoradiotherapy for HPV-related oropharyngeal squamous cell carcinoma of the head and neck.
    Oral Oncol. 2017;67:24-28.
    PubMed     Text format     Abstract available


  14. KINDT N, Descamps G, Seminerio I, Bellier J, et al
    High stromal Foxp3-positive T cell number combined to tumor stage improved prognosis in head and neck squamous cell carcinoma.
    Oral Oncol. 2017;67:183-191.
    PubMed     Text format     Abstract available


  15. POLESEL J, Furlan C, Birri S, Giacomarra V, et al
    The impact of time to treatment initiation on survival from head and neck cancer in north-eastern Italy.
    Oral Oncol. 2017;67:175-182.
    PubMed     Text format     Abstract available


  16. XIA WX, Liang H, Lv X, Wang L, et al
    Combining cetuximab with chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma: A propensity score analysis.
    Oral Oncol. 2017;67:167-174.
    PubMed     Text format     Abstract available


  17. CHAU L, Jabara JT, Lai W, Svider PF, et al
    Topical agents for oral cancer chemoprevention: A systematic review of the literature.
    Oral Oncol. 2017;67:153-159.
    PubMed     Text format     Abstract available


  18. DE FELICE F, Guerrero Urbano T
    New drug development in head and neck squamous cell carcinoma: The PI3-K inhibitors.
    Oral Oncol. 2017;67:119-123.
    PubMed     Text format     Abstract available


  19. KADLETZ L, Thurnher D, Wiebringhaus R, Erovic BM, et al
    Role of cancer stem-cell marker doublecortin-like kinase 1 in head and neck squamous cell carcinoma.
    Oral Oncol. 2017;67:109-118.
    PubMed     Text format     Abstract available


  20. KOFLER B, Borena W, Manzl C, Dudas J, et al
    Sensitivity of tumor surface brushings to detect human papilloma virus DNA in head and neck cancer.
    Oral Oncol. 2017;67:103-108.
    PubMed     Text format     Abstract available


  21. RASTOGI M, Sapru S, Gupta P, Gandhi AK, et al
    Prospective evaluation of Intensity Modulated Radiation Therapy with Simultaneous Integrated Boost (IMRT-SIB) in head and neck squamous cell carcinoma in patients not suitable for chemo-radiotherapy.
    Oral Oncol. 2017;67:10-16.
    PubMed     Text format     Abstract available


  22. HAMOIR M, Holvoet E, Ambroise J, Lengele B, et al
    Salvage surgery in recurrent head and neck squamous cell carcinoma: Oncologic outcome and predictors of disease free survival.
    Oral Oncol. 2017;67:1-9.
    PubMed     Text format     Abstract available


    March 2017
  23. BOONSTRA MC, Van Driel PB, Keereweer S, Prevoo HA, et al
    Preclinical uPAR-targeted multimodal imaging of locoregional oral cancer.
    Oral Oncol. 2017;66:1-8.
    PubMed     Text format     Abstract available


    February 2017
  24. PARK JS, Chang JW, Liu L, Jung SN, et al
    Clinical implications of microscopic extrathyroidal extension in patients with papillary thyroid carcinoma.
    Oral Oncol. 2017 Feb 17. pii: S1368-8375(17)30028.
    PubMed     Text format     Abstract available


  25. BELL RB, Gough MJ, Seung SK, Jutric Z, et al
    Erratum to 'Cytoreductive surgery for head and neck squamous cell carcinoma in the new age of immunotherapy' [Oral Oncol. 61 (2016) 166-176].
    Oral Oncol. 2017 Feb 12. pii: S1368-8375(17)30021.
    PubMed     Text format    


  26. CAO W, Liu JN, Liu Z, Wang X, et al
    A three-lncRNA signature derived from the Atlas of ncRNA in cancer (TANRIC) database predicts the survival of patients with head and neck squamous cell carcinoma.
    Oral Oncol. 2017;65:94-101.
    PubMed     Text format     Abstract available


  27. MASSA ST, Osazuwa-Peters N, Christopher KM, Arnold LD, et al
    Competing causes of death in the head and neck cancer population.
    Oral Oncol. 2017;65:8-15.
    PubMed     Text format     Abstract available


  28. RIEKE K, Schmid KK, Lydiatt W, Houfek J, et al
    Depression and survival in head and neck cancer patients.
    Oral Oncol. 2017;65:76-82.
    PubMed     Text format     Abstract available


  29. KRISHNAN AR, Korrapati A, Zou AE, Qu Y, et al
    Smoking status regulates a novel panel of PIWI-interacting RNAs in head and neck squamous cell carcinoma.
    Oral Oncol. 2017;65:68-75.
    PubMed     Text format     Abstract available


  30. O'BRIEN KM, Timmons A, Butow P, Gooberman-Hill R, et al
    Associations between neighbourhood support and financial burden with unmet needs of head and neck cancer survivors.
    Oral Oncol. 2017;65:57-64.
    PubMed     Text format     Abstract available


  31. KAINULAINEN S, Tornwall J, Koivusalo AM, Suominen AL, et al
    Dexamethasone in head and neck cancer patients with microvascular reconstruction: No benefit, more complications.
    Oral Oncol. 2017;65:45-50.
    PubMed     Text format     Abstract available


    January 2017
  32. LUCHINI C, Veronese N
    The importance of extranodal extension in metastatic head and neck squamous cell carcinoma, in the light of the new AJCC cancer staging system.
    Oral Oncol. 2017 Jan 9. pii: S1368-8375(16)30279.
    PubMed     Text format    


  33. SWICK AD, Stein AP, McCulloch TM, Hartig GK, et al
    Defining the boundaries and expanding the utility of head and neck cancer patient derived xenografts.
    Oral Oncol. 2017;64:65-72.
    PubMed     Text format     Abstract available


  34. BRAVI F, Polesel J, Garavello W, Serraino D, et al
    Adherence to the World Cancer Research Fund/American Institute for Cancer Research recommendations and head and neck cancers risk.
    Oral Oncol. 2017;64:59-64.
    PubMed     Text format     Abstract available


  35. VAN DEUDEKOM FJ, Schimberg AS, Kallenberg MH, Slingerland M, et al
    Functional and cognitive impairment, social environment, frailty and adverse health outcomes in older patients with head and neck cancer, a systematic review.
    Oral Oncol. 2017;64:27-36.
    PubMed     Text format     Abstract available


  36. LIU YC, Wang WY, Twu CW, Jiang RS, et al
    Prognostic impact of adjuvant chemotherapy in high-risk nasopharyngeal carcinoma patients.
    Oral Oncol. 2017;64:15-21.
    PubMed     Text format     Abstract available


  37. MORONEY LB, Helios J, Ward EC, Crombie J, et al
    Patterns of dysphagia and acute toxicities in patients with head and neck cancer undergoing helical IMRT+/-concurrent chemotherapy.
    Oral Oncol. 2017;64:1-8.
    PubMed     Text format     Abstract available


    December 2016
  38. D'SOUZA G, Anantharaman D, Gheit T, Abedi-Ardekani B, et al
    Corrigendum to 'Effect of HPV on head and neck cancer patient survival, by region and tumor site: A comparison of 1362 cases across three continents' [Oral Oncol. 62 (2016) 20-27].
    Oral Oncol. 2016 Dec 30. pii: S1368-8375(16)30270.
    PubMed     Text format    


  39. GALVAO-MOREIRA LV, da Cruz MC
    Corrigendum to "Oral microbiome, periodontitis and risk of head and neck cancer" [Oral Oncol. 53 (2016) 17-19].
    Oral Oncol. 2016 Dec 23. pii: S1368-8375(16)30266.
    PubMed     Text format    


  40. LI YJ, Lai WT, Chang CC, Kuo MY, et al
    Ataxia-telangiectasia mutated interactor regulates head and neck cancer metastasis via KRas expression.
    Oral Oncol. 2016 Dec 21. pii: S1368-8375(16)30214.
    PubMed     Text format     Abstract available


  41. YAMAMOTO VN, Thylur DS, Bauschard M, Schmale I, et al
    Overcoming radioresistance in head and neck squamous cell carcinoma.
    Oral Oncol. 2016;63:44-51.
    PubMed     Text format     Abstract available


  42. FERNANDEZ-MATEOS J, Seijas-Tamayo R, Mesia R, Taberna M, et al
    Epidermal growth factor receptor (EGFR) pathway polymorphisms as predictive markers of cetuximab toxicity in locally advanced head and neck squamous cell carcinoma (HNSCC) in a Spanish population.
    Oral Oncol. 2016;63:38-43.
    PubMed     Text format     Abstract available


  43. INGLEHART RC, Taberna M, Pickard RK, Hoff M, et al
    HPV knowledge gaps and information seeking by oral cancer patients.
    Oral Oncol. 2016;63:23-29.
    PubMed     Text format     Abstract available


  44. PATIL V, Joshi A, Noronha V, Deodhar J, et al
    Expectations and preferences for palliative chemotherapy in head and neck cancers patients.
    Oral Oncol. 2016;63:10-15.
    PubMed     Text format     Abstract available


    November 2016
  45. DASTE A, de Mones E, Digue L, Francois L, et al
    Immunotherapy in head and neck cancer: Need for a new strategy? Rapid progression with nivolumab then unexpected response with next treatment.
    Oral Oncol. 2016 Nov 3. pii: S1368-8375(16)30196.
    PubMed     Text format    


  46. PENG H, Chen L, Li WF, Zhang Y, et al
    Optimize the cycle of neoadjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma treated with intensity-modulated radiotherapy: A propensity score matching analysis.
    Oral Oncol. 2016;62:78-84.
    PubMed     Text format     Abstract available


  47. LIU L, Chang JW, Jung SN, Park HS, et al
    Clinical implications of the extent of BRAFV600E alleles in patients with papillary thyroid carcinoma.
    Oral Oncol. 2016;62:72-77.
    PubMed     Text format     Abstract available


  48. MERMOD M, Tolstonog G, Simon C, Monnier Y, et al
    Extracapsular spread in head and neck squamous cell carcinoma: A systematic review and meta-analysis.
    Oral Oncol. 2016;62:60-71.
    PubMed     Text format     Abstract available


  49. DEL BARCO MORILLO E, Mesia R, Adansa Klain JC, Vazquez Fernandez S, et al
    Phase II study of panitumumab and paclitaxel as first-line treatment in recurrent or metastatic head and neck cancer. TTCC-2009-03/VECTITAX study.
    Oral Oncol. 2016;62:54-59.
    PubMed     Text format     Abstract available


  50. BLANCHARD P, Volk RJ, Ringash J, Peterson SK, et al
    Assessing head and neck cancer patient preferences and expectations: A systematic review.
    Oral Oncol. 2016;62:44-53.
    PubMed     Text format     Abstract available


  51. CHENG SJ, Chang CF, Lee JJ, Chen HM, et al
    Hypermethylated ZNF582 and PAX1 are effective biomarkers for detection of oral dysplasia and oral cancer.
    Oral Oncol. 2016;62:34-43.
    PubMed     Text format     Abstract available


  52. SWARTZ JE, Pothen AJ, Wegner I, Smid EJ, et al
    Feasibility of using head and neck CT imaging to assess skeletal muscle mass in head and neck cancer patients.
    Oral Oncol. 2016;62:28-33.
    PubMed     Text format     Abstract available


  53. D'SOUZA G, Anantharaman D, Gheit T, Abedi-Ardekani B, et al
    Effect of HPV on head and neck cancer patient survival, by region and tumor site: A comparison of 1362 cases across three continents.
    Oral Oncol. 2016;62:20-27.
    PubMed     Text format     Abstract available


  54. KUO TJ, Chu CH, Tang PL, Lai YC, et al
    Effects of geographic area and socioeconomic status in Taiwan on survival rates of head and neck cancer patients after radiotherapy.
    Oral Oncol. 2016;62:136-138.
    PubMed     Text format    


  55. NAIK PP, Das DN, Panda PK, Mukhopadhyay S, et al
    Implications of cancer stem cells in developing therapeutic resistance in oral cancer.
    Oral Oncol. 2016;62:122-135.
    PubMed     Text format     Abstract available


  56. OU D, Blanchard P, El Khoury C, De Felice F, et al
    Induction chemotherapy with docetaxel, cisplatin and fluorouracil followed by concurrent chemoradiotherapy or chemoradiotherapy alone in locally advanced non-endemic nasopharyngeal carcinoma.
    Oral Oncol. 2016;62:114-121.
    PubMed     Text format     Abstract available


  57. LIM YC, Liu L, Chang JW, Koo BS, et al
    Lateral lymph node recurrence after total thyroidectomy and central neck dissection in patients with papillary thyroid cancer without clinical evidence of lateral neck metastasis.
    Oral Oncol. 2016;62:109-113.
    PubMed     Text format     Abstract available


  58. KINDT N, Descamps G, Seminerio I, Bellier J, et al
    Langerhans cell number is a strong and independent prognostic factor for head and neck squamous cell carcinomas.
    Oral Oncol. 2016;62:1-10.
    PubMed     Text format     Abstract available


    October 2016
  59. EDER-CZEMBIREK C, Czembirek C, Selzer E
    Erratum to "Neoadjuvant radiotherapy plus radical surgery for locally advanced stage III/IV oral cancer: Analysis of prognostic factors affecting overall survival" [Oral Oncol. 60 (2016) 1-7].
    Oral Oncol. 2016 Oct 31. pii: S1368-8375(16)30192.
    PubMed     Text format    


  60. LOW GM, Thylur DS, Yamamoto V, Sinha UK, et al
    Erratum to "The effect of human papillomavirus on DNA repair in head and neck squamous cell carcinoma" [Oral Oncol. 61 (2016) 27-30].
    Oral Oncol. 2016 Oct 31. pii: S1368-8375(16)30193.
    PubMed     Text format    


  61. BAXI SS, Dunn LA, Burtness BA
    Amidst the excitement: A cautionary tale of immunotherapy, pseudoprogression and head and neck squamous cell carcinoma.
    Oral Oncol. 2016 Oct 21. pii: S1368-8375(16)30182.
    PubMed     Text format    


  62. ZOLKIND P, Dunn GP, Lin T, Griffith M, et al
    Neoantigens in immunotherapy and personalized vaccines: Implications for head and neck squamous cell carcinoma.
    Oral Oncol. 2016 Oct 14. pii: S1368-8375(16)30175.
    PubMed     Text format     Abstract available


  63. MATHIALAGAN A, Verma RK, Panda NK
    Comparison of spinal accessory dysfunction following neck dissection with harmonic scalpel and electrocautery - A randomized study.
    Oral Oncol. 2016;61:142-5.
    PubMed     Text format     Abstract available


  64. ADHAULIYA N, Kalappanavar AN, Ali IM, Annigeri RG, et al
    Autophagy: A boon or bane in oral cancer.
    Oral Oncol. 2016;61:120-6.
    PubMed     Text format     Abstract available


  65. DIVI V, Tao L, Whittemore A, Oakley-Girvan I, et al
    Geographic variation in Medicare treatment costs and outcomes for advanced head and neck cancer.
    Oral Oncol. 2016;61:83-8.
    PubMed     Text format     Abstract available


  66. HAGEDOORN P, Vandenheede H, Vanthomme K, Willaert D, et al
    A cohort study into head and neck cancer mortality in Belgium (2001-11): Are individual socioeconomic differences conditional on area deprivation?
    Oral Oncol. 2016;61:76-82.
    PubMed     Text format     Abstract available


  67. PURKAYASTHA M, McMahon AD, Gibson J, Conway DI, et al
    Trends of oral cavity, oropharyngeal and laryngeal cancer incidence in Scotland (1975-2012) - A socioeconomic perspective.
    Oral Oncol. 2016;61:70-5.
    PubMed     Text format     Abstract available


  68. CHAMCHOD S, Fuller CD, Mohamed AS, Grossberg A, et al
    Quantitative body mass characterization before and after head and neck cancer radiotherapy: A challenge of height-weight formulae using computed tomography measurement.
    Oral Oncol. 2016;61:62-9.
    PubMed     Text format     Abstract available


  69. FIGUEIREDO RA, Weiderpass E, Tajara EH, Strom P, et al
    Diabetes mellitus, metformin and head and neck cancer.
    Oral Oncol. 2016;61:47-54.
    PubMed     Text format     Abstract available


  70. WIRTH LJ, Dakhil S, Kornek G, Axelrod R, et al
    PARTNER: An open-label, randomized, phase 2 study of docetaxel/cisplatin chemotherapy with or without panitumumab as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck.
    Oral Oncol. 2016;61:31-40.
    PubMed     Text format     Abstract available


  71. LOW GM, Thylur DS, N Yamamoto V, Sinha UK, et al
    The effect of human papillomavirus on DNA repair in head and neck squamous cell carcinoma.
    Oral Oncol. 2016;61:27-30.
    PubMed     Text format     Abstract available


  72. SINEVICI N, O'sullivan J
    Oral cancer: Deregulated molecular events and their use as biomarkers.
    Oral Oncol. 2016;61:12-8.
    PubMed     Text format     Abstract available


  73. SCHMIDT H, Kulasinghe A, Kenny L, Punyadeera C, et al
    The development of a liquid biopsy for head and neck cancers.
    Oral Oncol. 2016;61:8-11.
    PubMed     Text format     Abstract available


  74. ADKINS D, Ley J, Michel L, Wildes TM, et al
    nab-Paclitaxel, cisplatin, and 5-fluorouracil followed by concurrent cisplatin and radiation for head and neck squamous cell carcinoma.
    Oral Oncol. 2016;61:1-7.
    PubMed     Text format     Abstract available


    September 2016
  75. RANCOULE C, Vallard A, Espenel S, Guy JB, et al
    Immunotherapy in head and neck cancer: Harnessing profit on a system disruption.
    Oral Oncol. 2016 Sep 9. pii: S1368-8375(16)30154.
    PubMed     Text format     Abstract available


  76. BRYAN BELL R, Gough MJ, Seung SK, Jutric Z, et al
    Cytoreductive surgery for head and neck squamous cell carcinoma in the new age of immunotherapy.
    Oral Oncol. 2016 Sep 7. pii: S1368-8375(16)30149.
    PubMed     Text format     Abstract available


  77. MANSHA MA, Abbasi AN, Ali N, Hafiz A, et al
    Correspondence on review article published in Oral Oncology (Vol. 59, August 2016): "Evaluation of the benefit and use of multidisciplinary teams in the treatment of head and neck cancer."
    Oral Oncol. 2016 Sep 6. pii: S1368-8375(16)30152.
    PubMed     Text format    


  78. LIN Y, Mallen-St Clair J, Wang G, Luo J, et al
    p38 MAPK mediates epithelial-mesenchymal transition by regulating p38IP and Snail in head and neck squamous cell carcinoma.
    Oral Oncol. 2016;60:81-9.
    PubMed     Text format     Abstract available


  79. LEE JY, Suresh K, Nguyen R, Sapir E, et al
    Predictors of severe long-term toxicity after re-irradiation for head and neck cancer.
    Oral Oncol. 2016;60:32-40.
    PubMed     Text format     Abstract available


  80. MADATHIL SA, Rousseau MC, Wynant W, Schlecht NF, et al
    Nonlinear association between betel quid chewing and oral cancer: Implications for prevention.
    Oral Oncol. 2016;60:25-31.
    PubMed     Text format     Abstract available


  81. LU L, Li J, Zhao C, Xue W, et al
    Prognostic efficacy of combining tumor volume with Epstein-Barr virus DNA in patients treated with intensity-modulated radiotherapy for nasopharyngeal carcinoma.
    Oral Oncol. 2016;60:18-24.
    PubMed     Text format     Abstract available


  82. PANDA S, Padhiary SK, Routray S
    Chemokines accentuating protumoral activities in oral cancer microenvironment possess an imperious stratagem for therapeutic resolutions.
    Oral Oncol. 2016;60:8-17.
    PubMed     Text format     Abstract available


  83. CHRISTINA EC, Cornelia C, Edgar S
    Neoadjuvant radiotherapy plus radical surgery for locally advanced stage III/IV oral cancer: Analysis of prognostic factors affecting overall survival.
    Oral Oncol. 2016;60:1-7.
    PubMed     Text format     Abstract available


    August 2016
  84. DASTE A, de Mones E, Dupin C, Francois L, et al
    m-TOR inhibitor as potential radiosensitizer for head and neck squamous cell carcinoma: A case report of an organ transplant patient and review of the literature.
    Oral Oncol. 2016 Aug 30. pii: S1368-8375(16)30136.
    PubMed     Text format    


  85. SZTURZ P, Faivre S
    Letter to the editor referring to the publication entitled "The role of antagonists of the PD-1:PD-L1/PD-L2 axis in head and neck cancer treatment" by Pai et al.
    Oral Oncol. 2016 Aug 28. pii: S1368-8375(16)30135.
    PubMed     Text format    


  86. PAI SI, Zandberg DP, Strome SE
    The role of antagonists of the PD-1:PD-L1/PD-L2 axis in head and neck cancer treatment.
    Oral Oncol. 2016 Aug 5. pii: S1368-8375(16)30119.
    PubMed     Text format     Abstract available


  87. LICITRA L, Keilholz U, Tahara M, Lin JC, et al
    Evaluation of the benefit and use of multidisciplinary teams in the treatment of head and neck cancer.
    Oral Oncol. 2016;59:73-9.
    PubMed     Text format     Abstract available


  88. RADES D, Seidl D, Janssen S, Bajrovic A, et al
    Chemoradiation of locally advanced squamous cell carcinoma of the head-and-neck (LASCCHN): Is 20mg/m(2) cisplatin on five days every four weeks an alternative to 100mg/m(2) cisplatin every three weeks?
    Oral Oncol. 2016;59:67-72.
    PubMed     Text format     Abstract available


  89. NOHATA N, Abba MC, Gutkind JS
    Unraveling the oral cancer lncRNAome: Identification of novel lncRNAs associated with malignant progression and HPV infection.
    Oral Oncol. 2016;59:58-66.
    PubMed     Text format     Abstract available


  90. OU D, Levy A, Blanchard P, Nguyen F, et al
    Concurrent chemoradiotherapy with cisplatin or cetuximab for locally advanced head and neck squamous cell carcinomas: Does human papilloma virus play a role?
    Oral Oncol. 2016;59:50-7.
    PubMed     Text format     Abstract available


  91. OOSTING SF, Chen TW, Huang SH, Wang L, et al
    A comparison of weekly versus 3-weekly cisplatin during adjuvant radiotherapy for high-risk head and neck cancer.
    Oral Oncol. 2016;59:43-9.
    PubMed     Text format     Abstract available


  92. PRINCE ME, Zhou L, Moyer JS, Tao H, et al
    Evaluation of the immunogenicity of ALDH(high) human head and neck squamous cell carcinoma cancer stem cells in vitro.
    Oral Oncol. 2016;59:30-42.
    PubMed     Text format     Abstract available


    July 2016
  93. TERENZI V, Cassoni A, Della Monaca M, Priore P, et al
    Oral cancer during pregnancy.
    Oral Oncol. 2016 Jul 2. pii: S1368-8375(16)30092.
    PubMed     Text format    


  94. MICHEL L, Ley J, Wildes TM, Schaffer A, et al
    Phase I trial of palbociclib, a selective cyclin dependent kinase 4/6 inhibitor, in combination with cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma.
    Oral Oncol. 2016;58:41-8.
    PubMed     Text format     Abstract available


  95. WANG K, Amdur RJ, Mendenhall WM, Green R, et al
    Impact of post-chemoradiotherapy superselective/selective neck dissection on patient reported quality of life.
    Oral Oncol. 2016;58:21-6.
    PubMed     Text format     Abstract available


  96. SUROV A, Stumpp P, Meyer HJ, Gawlitza M, et al
    Simultaneous (18)F-FDG-PET/MRI: Associations between diffusion, glucose metabolism and histopathological parameters in patients with head and neck squamous cell carcinoma.
    Oral Oncol. 2016;58:14-20.
    PubMed     Text format     Abstract available


    June 2016
  97. SZTURZ P, Raymond E, Faivre S
    c-MET-mediated resistance to EGFR inhibitors in head and neck cancer: How to move from bench to bedside.
    Oral Oncol. 2016 Jun 11. pii: S1368-8375(16)30063.
    PubMed     Text format    


  98. KUO TJ, Ko WT, Chang YC, Lai YC, et al
    Risk of osteoradionecrosis in head and neck cancers: Comparison between oral and non-oral cancers.
    Oral Oncol. 2016 Jun 10. pii: S1368-8375(16)30064.
    PubMed     Text format    


  99. RADES D, Seidl D, Janssen S, Bajrovic A, et al
    Do we need 5-FU in addition to cisplatin for chemoradiation of locally advanced head-and-neck cancer?
    Oral Oncol. 2016;57:40-5.
    PubMed     Text format     Abstract available


  100. IQBAL H, Pan Q
    Image guided surgery in the management of head and neck cancer.
    Oral Oncol. 2016;57:32-9.
    PubMed     Text format     Abstract available


  101. RANSOHOFF A, Wood D, Solomon Henry A, Divi V, et al
    Third party assessment of resection margin status in head and neck cancer.
    Oral Oncol. 2016;57:27-31.
    PubMed     Text format     Abstract available


  102. WARD MC, Adelstein DJ, Bhateja P, Nwizu TI, et al
    Severe late dysphagia and cause of death after concurrent chemoradiation for larynx cancer in patients eligible for RTOG 91-11.
    Oral Oncol. 2016;57:21-6.
    PubMed     Text format     Abstract available


    May 2016
  103. T PARSONS J, D Greene B
    Induction chemotherapy for head and neck squamous cell carcinoma.
    Oral Oncol. 2016 May 30. pii: S1368-8375(16)30052.
    PubMed     Text format    


  104. UPPALURI R, Bell RB, Sunwoo JB
    Head and neck cancer immunology and immunotherapeutics: Basic concepts to clinical translational approaches.
    Oral Oncol. 2016 May 26. pii: S1368-8375(16)30050.
    PubMed     Text format    


  105. DAVIS RJ, Van Waes C, Allen CT
    Overcoming barriers to effective immunotherapy: MDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancer.
    Oral Oncol. 2016 May 20. pii: S1368-8375(16)30045.
    PubMed     Text format     Abstract available


  106. HASSONA Y, Abu Ghosh M, Abu Ghlassi T, Scully C, et al
    Public engagement with oral cancer on Facebook.
    Oral Oncol. 2016 May 6. pii: S1368-8375(16)30034.
    PubMed     Text format    


  107. TEPPER SR, Zuo Z, Khattri A, Hess J, et al
    Growth factor expression mediates resistance to EGFR inhibitors in head and neck squamous cell carcinomas.
    Oral Oncol. 2016;56:62-70.
    PubMed     Text format     Abstract available


  108. OOFT ML, van Ipenburg J, Braunius WW, Stegeman I, et al
    A nation-wide epidemiological study on the risk of developing second malignancies in patients with different histological subtypes of nasopharyngeal carcinoma.
    Oral Oncol. 2016;56:40-6.
    PubMed     Text format     Abstract available


  109. DATTA J, Islam M, Dutta S, Roy S, et al
    Suberoylanilide hydroxamic acid inhibits growth of head and neck cancer cell lines by reactivation of tumor suppressor microRNAs.
    Oral Oncol. 2016;56:32-9.
    PubMed     Text format     Abstract available


  110. LAROCCA CJ, Han J, Salzwedel AO, Davydova J, et al
    Oncolytic adenoviruses targeted to Human Papilloma Virus-positive head and neck squamous cell carcinomas.
    Oral Oncol. 2016;56:25-31.
    PubMed     Text format     Abstract available


  111. DA SILVA JM, Soave DF, Moreira Dos Santos TP, Batista AC, et al
    Significance of chemokine and chemokine receptors in head and neck squamous cell carcinoma: A critical review.
    Oral Oncol. 2016;56:8-16.
    PubMed     Text format     Abstract available


  112. FENG Y, Li Y, Zhang Y, Zheng H, et al
    Association of genetic variants with tumor HPV16 status and survival in squamous cell carcinoma of the oropharynx.
    Oral Oncol. 2016;56:78-83.
    PubMed     Text format     Abstract available


  113. KUO TJ, Leung CM, Chang HS, Wu CN, et al
    Jaw osteoradionecrosis and dental extraction after head and neck radiotherapy: A nationwide population-based retrospective study in Taiwan.
    Oral Oncol. 2016;56:71-7.
    PubMed     Text format     Abstract available


  114. YANG CC, Tu HF, Wu CH, Chang HC, et al
    Up-regulation of HB-EGF by the COX-2/PGE2 signaling associates with the cisplatin resistance and tumor recurrence of advanced HNSCC.
    Oral Oncol. 2016;56:54-61.
    PubMed     Text format     Abstract available


  115. ZAFEREO ME, Xu L, Dahlstrom KR, Viamonte CA, et al
    Squamous cell carcinoma of the oral cavity often overexpresses p16 but is rarely driven by human papillomavirus.
    Oral Oncol. 2016;56:47-53.
    PubMed     Text format     Abstract available


  116. SHARMA S, Bekelman J, Lin A, Lukens JN, et al
    Clinical impact of prolonged diagnosis to treatment interval (DTI) among patients with oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2016;56:17-24.
    PubMed     Text format     Abstract available


  117. AMINI A, Jasem J, Jones BL, Robin TP, et al
    Predictors of overall survival in human papillomavirus-associated oropharyngeal cancer using the National Cancer Data Base.
    Oral Oncol. 2016;56:1-7.
    PubMed     Text format     Abstract available


    April 2016
  118. ABBOTT D, Cohen E, Sadeghi N, Stein K, et al
    Considering the survivorship care needs of head and neck cancer survivors.
    Oral Oncol. 2016 Apr 26. pii: S1368-8375(16)30032.
    PubMed     Text format    


  119. ETTL T, El-Gindi A, Hautmann M, Gosau M, et al
    Positive frozen section margins predict local recurrence in R0-resected squamous cell carcinoma of the head and neck.
    Oral Oncol. 2016;55:17-23.
    PubMed     Text format     Abstract available


  120. PIERCE CAMPBELL CM, Giuliano AR, Torres BN, O'Keefe MT, et al
    Salivary secretory leukocyte protease inhibitor (SLPI) and head and neck cancer: The Cancer Prevention Study II Nutrition Cohort.
    Oral Oncol. 2016;55:1-5.
    PubMed     Text format     Abstract available


  121. ROOPER LM, Gandhi M, Bishop JA, Westra WH, et al
    RNA in-situ hybridization is a practical and effective method for determining HPV status of oropharyngeal squamous cell carcinoma including discordant cases that are p16 positive by immunohistochemistry but HPV negative by DNA in-situ hybridization.
    Oral Oncol. 2016;55:11-6.
    PubMed     Text format     Abstract available


  122. ELHAKIM MT, Breinholt H, Godballe C, Andersen LJ, et al
    Polymorphous low-grade adenocarcinoma: A Danish national study.
    Oral Oncol. 2016;55:6-10.
    PubMed     Text format     Abstract available


  123. LINARES J, Rullan A, Taberna M, Vazquez S, et al
    Emergence of long-term surviving patients with the introduction of Cetuximab in recurrent/metastatic disease of squamous cell carcinoma of head and neck.
    Oral Oncol. 2016;55:e4.
    PubMed     Text format    


  124. POLEDNAK AP
    Evidence for a stabilization of incidence rates for base of tongue and tonsil carcinoma in the U.S. white population.
    Oral Oncol. 2016;55:e5-6.
    PubMed     Text format    


  125. KANG H, Kwon M, Park JJ, Kim JP, et al
    Clinical implications of human papilloma virus and other biologic markers in nasopharyngeal cancer.
    Oral Oncol. 2016;55:e7-e10.
    PubMed     Text format    


  126. KUK SK, Yoon HJ, Hong SD, Hong SP, et al
    Staging significance of bone invasion in small-sized (4cm or less) oral squamous cell carcinoma as defined by the American Joint Committee on Cancer.
    Oral Oncol. 2016;55:31-6.
    PubMed     Text format     Abstract available


  127. AHN PH, Quon H, O'Malley BW, Weinstein G, et al
    Toxicities and early outcomes in a phase 1 trial of photodynamic therapy for premalignant and early stage head and neck tumors.
    Oral Oncol. 2016;55:37-42.
    PubMed     Text format     Abstract available


  128. HEIDUSCHKA G, Virk SA, Palme CE, Ch'ng S, et al
    Margin to tumor thickness ratio - A predictor of local recurrence and survival in oral squamous cell carcinoma.
    Oral Oncol. 2016;55:49-54.
    PubMed     Text format     Abstract available


    March 2016
  129. PATIL VM, Joshi A, Noronha V, Karpe A, et al
    Technically unresectable recurrent oral cancers: Is NACT the answer?
    Oral Oncol. 2016 Mar 31. pii: S1368-8375(16)30008.
    PubMed     Text format    


  130. HU X, Zhang Q, Hua H, Chen F, et al
    Changes in the salivary microbiota of oral leukoplakia and oral cancer.
    Oral Oncol. 2016 Mar 26. pii: S1368-8375(16)00052.
    PubMed     Text format    


  131. TRZASKOWSKA-KOMON E, Wasiak M, Rolinski J, Klatka J, et al
    Dendritic cells generated from peripheral blood monocytes (Mo-DCs) and stimulated with laryngeal cancer cell lysates are not good enough in stimulating anti-tumor immunity.
    Oral Oncol. 2016 Mar 7. pii: S1368-8375(16)00036.
    PubMed     Text format    


  132. DE FELICE F, Musio D, Tombolini V
    Intra-operative radiation therapy (IORT) in recurrent head and neck cancer.
    Oral Oncol. 2016 Mar 3. pii: S1368-8375(16)00042.
    PubMed     Text format    


  133. GANJRE AP, Sarode GS
    Third hand smoke--A hidden demon.
    Oral Oncol. 2016;54:e3-4.
    PubMed     Text format    


  134. ROWAN NR, Johnson JT, Fratangelo CE, Smith BK, et al
    Utility of a perioperative nutritional intervention on postoperative outcomes in high-risk head & neck cancer patients.
    Oral Oncol. 2016;54:42-6.
    PubMed     Text format     Abstract available


  135. SEDGHIZADEH PP, Billington WD, Paxton D, Ebeed R, et al
    Is p16-positive oropharyngeal squamous cell carcinoma associated with favorable prognosis? A systematic review and meta-analysis.
    Oral Oncol. 2016;54:15-27.
    PubMed     Text format     Abstract available


  136. SHER DJ, Schwartz DL, Nedzi L, Khan S, et al
    Comparative effectiveness of induction chemotherapy for oropharyngeal squamous cell carcinoma: A population-based analysis.
    Oral Oncol. 2016;54:58-67.
    PubMed     Text format     Abstract available


  137. OZRETIC L, Wagner S, Huebbers CU, Gattenlohner S, et al
    FGFR1 amplification and co-overexpression of c-MYC in oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2016;54:e7-9.
    PubMed     Text format    


  138. HAHLBROCK A, Goesswein D, Kunzel J, Wunsch D, et al
    Threonine Aspartase1: An unexplored protease with relevance for oral oncology?
    Oral Oncol. 2016;54:e10-2.
    PubMed     Text format    


  139. HOSNI A, Huang SH, Goldstein D, Xu W, et al
    Outcomes and prognostic factors for major salivary gland carcinoma following postoperative radiotherapy.
    Oral Oncol. 2016;54:75-80.
    PubMed     Text format     Abstract available


    February 2016
  140. KRAAIJENGA SA, Oskam IM, van Son RJ, Hamming-Vrieze O, et al
    Assessment of voice, speech, and related quality of life in advanced head and neck cancer patients 10-years+ after chemoradiotherapy.
    Oral Oncol. 2016 Feb 10. pii: S1368-8375(16)00019.
    PubMed     Text format     Abstract available


  141. FIRMINO N, Martinez VD, Rowbotham DA, Enfield KS, et al
    HPV status is associated with altered PIWI-interacting RNA expression pattern in head and neck cancer.
    Oral Oncol. 2016 Feb 4. pii: S1368-8375(16)00015.
    PubMed     Text format     Abstract available


  142. SONIS ST, Hashemi S, Epstein JB, Nair RG, et al
    Could the biological robustness of low level laser therapy (Photobiomodulation) impact its use in the management of mucositis in head and neck cancer patients.
    Oral Oncol. 2016 Feb 3. pii: S1368-8375(16)00008.
    PubMed     Text format     Abstract available


  143. SARODE GS, Sarode SC
    Superficial mucoceles at surgical mucosal margins of excised oral cancer specimens: An unexpected finding.
    Oral Oncol. 2016 Feb 2. pii: S1368-8375(16)00005.
    PubMed     Text format    


  144. HUANG YC, Lee YC, Tseng PH, Chen TC, et al
    Regular screening of esophageal cancer for 248 newly diagnosed hypopharyngeal squamous cell carcinoma by unsedated transnasal esophagogastroduodenoscopy.
    Oral Oncol. 2016 Feb 1. pii: S1368-8375(16)00011.
    PubMed     Text format     Abstract available


  145. YIN ZZ, Gao L, Luo JW, Yi JL, et al
    Long-term outcomes of patients with esthesioneuroblastomas: A cohort from a single institution.
    Oral Oncol. 2016;53:48-53.
    PubMed     Text format     Abstract available


  146. SHRIDHAR K, Walia GK, Aggarwal A, Gulati S, et al
    DNA methylation markers for oral pre-cancer progression: A critical review.
    Oral Oncol. 2016;53:1-9.
    PubMed     Text format     Abstract available


  147. ZHU GA, Lira R, Colevas AD
    Discordance in routine second opinion pathology review of head and neck oncology specimens: A single-center five year retrospective review.
    Oral Oncol. 2016;53:36-41.
    PubMed     Text format     Abstract available


  148. HUNG KF, Liu CJ, Chiu PC, Lin JS, et al
    MicroRNA-31 upregulation predicts increased risk of progression of oral potentially malignant disorder.
    Oral Oncol. 2016;53:42-7.
    PubMed     Text format     Abstract available


  149. ZHOU X, Su YX, Lao XM, Liang YJ, et al
    CD19(+)IL-10(+) regulatory B cells affect survival of tongue squamous cell carcinoma patients and induce resting CD4(+) T cells to CD4(+)Foxp3(+) regulatory T cells.
    Oral Oncol. 2016;53:27-35.
    PubMed     Text format     Abstract available


  150. MUCKE T, Kanatas A, Ritschl LM, Koerdt S, et al
    Tumor thickness and risk of lymph node metastasis in patients with squamous cell carcinoma of the tongue.
    Oral Oncol. 2016;53:80-4.
    PubMed     Text format     Abstract available


    January 2016
  151. DEL FABBRO M, Marcazzan S, D'Antico S, Weinstein RL, et al
    Autologous platelet concentrates in head and neck cancer surgery: Are such bio-adjuvants really safe?
    Oral Oncol. 2016 Jan 25. pii: S1368-8375(16)00012.
    PubMed     Text format    


  152. WALL LR, Cartmill B, Ward EC, Hill AJ, et al
    "ScreenIT": Computerized screening of swallowing, nutrition and distress in head and neck cancer patients during (chemo)radiotherapy.
    Oral Oncol. 2016 Jan 20. pii: S1368-8375(16)00007.
    PubMed     Text format     Abstract available


  153. SHIMANE T, Aizawa H, Koike T, Kamiya M, et al
    Oral cancer intraoperative detection by topically spraying a gamma-glutamyl transpeptidase-activated fluorescent probe.
    Oral Oncol. 2016 Jan 19. pii: S1368-8375(15)00429.
    PubMed     Text format    


  154. ANAND R, Sarode GS, Sarode SC
    Chronic stress and oral cancer research: Disregarded aspects in animal model studies.
    Oral Oncol. 2016 Jan 18. pii: S1368-8375(16)00006.
    PubMed     Text format    


  155. BERGAMINI C, Locati L, Bossi P, Granata R, et al
    Does a multidisciplinary team approach in a tertiary referral centre impact on the initial management of head and neck cancer?
    Oral Oncol. 2016 Jan 13. pii: S1368-8375(16)00002.
    PubMed     Text format     Abstract available


  156. MAZUREK AM, Rutkowski T, Fiszer-Kierzkowska A, Malusecka E, et al
    Assessment of the total cfDNA and HPV16/18 detection in plasma samples of head and neck squamous cell carcinoma patients.
    Oral Oncol. 2016 Jan 11. pii: S1368-8375(15)00428.
    PubMed     Text format     Abstract available


  157. COSWAY B, Lovat P
    The role of autophagy in squamous cell carcinoma of the head and neck.
    Oral Oncol. 2016 Jan 7. pii: S1368-8375(15)00433.
    PubMed     Text format     Abstract available


  158. SAMUELS SE, Tao Y, Lyden T, Haxer M, et al
    Comparisons of dysphagia and quality of life (QOL) in comparable patients with HPV-positive oropharyngeal cancer receiving chemo-irradiation or cetuximab-irradiation.
    Oral Oncol. 2016 Jan 5. pii: S1368-8375(15)00416.
    PubMed     Text format     Abstract available


  159. WEBER M, Iliopoulos C, Moebius P, Buttner-Herold M, et al
    Prognostic significance of macrophage polarization in early stage oral squamous cell carcinomas.
    Oral Oncol. 2016;52:75-84.
    PubMed     Text format     Abstract available


  160. LIU JT, Kann BH, De B, Buckstein M, et al
    Prognostic value of radiographic extracapsular extension in locally advanced head and neck squamous cell cancers.
    Oral Oncol. 2016;52:52-7.
    PubMed     Text format     Abstract available


  161. KESHET N, Abu-Tair J, Zaharia B, Abdalla-Aslan R, et al
    Superficial oral mucoceles in cancer patient after radiation therapy: An overlooked yet imperative phenomenon.
    Oral Oncol. 2016;52:e1-2.
    PubMed     Text format    


  162. GUO T, Rettig E, Fakhry C
    Understanding the impact of survival and human papillomavirus tumor status on timing of recurrence in oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2016;52:97-103.
    PubMed     Text format     Abstract available


  163. VAN MONSJOU HS, Schaapveld M, Hamming-Vrieze O, de Boer JP, et al
    Cause-specific excess mortality in patients treated for cancer of the oral cavity and oropharynx: A population-based study.
    Oral Oncol. 2016;52:37-44.
    PubMed     Text format     Abstract available


  164. SCHWAM ZG, Judson BL
    Improved prognosis for patients with oral cavity squamous cell carcinoma: Analysis of the National Cancer Database 1998-2006.
    Oral Oncol. 2016;52:45-51.
    PubMed     Text format     Abstract available


  165. YU V, Rahimy M, Korrapati A, Xuan Y, et al
    Electronic cigarettes induce DNA strand breaks and cell death independently of nicotine in cell lines.
    Oral Oncol. 2016;52:58-65.
    PubMed     Text format     Abstract available


  166. ZHAN KY, Nicolli EA, Khaja SF, Day TA, et al
    Lymphoepithelial carcinoma of the major salivary glands: Predictors of survival in a non-endemic region.
    Oral Oncol. 2016;52:24-9.
    PubMed     Text format     Abstract available


    December 2015
  167. GEIGER JL, Grandis JR, Bauman JE
    The STAT3 pathway as a therapeutic target in head and neck cancer: Barriers and innovations.
    Oral Oncol. 2015 Dec 27. pii: S1368-8375(15)00412.
    PubMed     Text format     Abstract available


  168. AHN MJ, D'Cruz A, Vermorken JB, Chen JP, et al
    Clinical recommendations for defining platinum unsuitable head and neck cancer patient populations on chemoradiotherapy: A literature review.
    Oral Oncol. 2015 Dec 19. pii: S1368-8375(15)00397.
    PubMed     Text format     Abstract available


  169. WOODY NM, Koyfman SA, Xia P, Yu N, et al
    Regional control is preserved after dose de-escalated radiotherapy to involved lymph nodes in HPV positive oropharyngeal cancer.
    Oral Oncol. 2015 Dec 17. pii: S1368-8375(15)00370.
    PubMed     Text format     Abstract available


  170. BOWLES DW, Keysar SB, Eagles JR, Wang G, et al
    A pilot study of cetuximab and the hedgehog inhibitor IPI-926 in recurrent/metastatic head and neck squamous cell carcinoma.
    Oral Oncol. 2015 Dec 15. pii: S1368-8375(15)00392.
    PubMed     Text format     Abstract available


  171. CHUNG CH, Rudek MA, Kang H, Marur S, et al
    A phase I study afatinib/carboplatin/paclitaxel induction chemotherapy followed by standard chemoradiation in HPV-negative or high-risk HPV-positive locally advanced stage III/IVa/IVb head and neck squamous cell carcinoma.
    Oral Oncol. 2015 Dec 15. pii: S1368-8375(15)00398.
    PubMed     Text format     Abstract available


  172. GALVAO-MOREIRA LV, da Cruz MC
    Oral microbiome, periodontitis and risk of head and neck cancer.
    Oral Oncol. 2015 Dec 10. pii: S1368-8375(15)00391.
    PubMed     Text format     Abstract available


  173. LEE MS, Nelson AM, Thompson LM, Donovan KA, et al
    Supportive care needs of oral cancer survivors: Prevalence and correlates.
    Oral Oncol. 2015 Dec 9. pii: S1368-8375(15)00385.
    PubMed     Text format     Abstract available


  174. SETTON J, Han J, Kannarunimit D, Wuu YR, et al
    Long-term patterns of relapse and survival following definitive intensity-modulated radiotherapy for non-endemic nasopharyngeal carcinoma.
    Oral Oncol. 2015 Dec 7. pii: S1368-8375(15)00393.
    PubMed     Text format     Abstract available


    November 2015
  175. VAN DER LINDEN N, Flach GB, de Bree R, Uyl-de Groot CA, et al
    Cost-utility of sentinel lymph node biopsy in cT1-T2N0 oral cancer.
    Oral Oncol. 2015 Nov 26. pii: S1368-8375(15)00389.
    PubMed     Text format     Abstract available


  176. BELL RB, Leidner RS, Crittenden MR, Curti BD, et al
    OX40 signaling in head and neck squamous cell carcinoma: Overcoming immunosuppression in the tumor microenvironment.
    Oral Oncol. 2015 Nov 21. pii: S1368-8375(15)00387.
    PubMed     Text format     Abstract available


  177. CHANG JW, Gwak SY, Shim GA, Liu L, et al
    EZH2 is associated with poor prognosis in head-and-neck squamous cell carcinoma via regulating the epithelial-to-mesenchymal transition and chemosensitivity.
    Oral Oncol. 2015 Nov 18. pii: S1368-8375(15)00368.
    PubMed     Text format     Abstract available


  178. RYLANDS J, Lowe D, Rogers SN
    Outcomes by area of residence deprivation in a cohort of oral cancer patients: Survival, health-related quality of life, and place of death.
    Oral Oncol. 2015 Nov 12. pii: S1368-8375(15)00361.
    PubMed     Text format     Abstract available


  179. LICITRA L, Mesia R, Keilholz U
    Individualised quality of life as a measure to guide treatment choices in squamous cell carcinoma of the head and neck.
    Oral Oncol. 2015 Nov 11. pii: S1368-8375(15)00364.
    PubMed     Text format     Abstract available


  180. PEDERSEN A, Wilson J, McColl E, Carding P, et al
    Swallowing outcome measures in head and neck cancer - How do they compare?
    Oral Oncol. 2015 Nov 9. pii: S1368-8375(15)00359.
    PubMed     Text format     Abstract available


  181. LANGIUS JA, Twisk J, Kampman M, Doornaert P, et al
    Prediction model to predict critical weight loss in patients with head and neck cancer during (chemo)radiotherapy.
    Oral Oncol. 2015 Nov 9. pii: S1368-8375(15)00365.
    PubMed     Text format     Abstract available


    October 2015
  182. TAKES RP, Wierzbicka M, D'Souza G, Jackowska J, et al
    HPV vaccination to prevent oropharyngeal carcinoma: What can be learned from anogenital vaccination programs?
    Oral Oncol. 2015 Oct 28. pii: S1368-8375(15)00355.
    PubMed     Text format     Abstract available


  183. LEE YS, Park JY, Cho KJ, Kim SB, et al
    Composition of inflammatory cells regulating the response to concurrent chemoradiation therapy for HPV (+) tonsil cancer.
    Oral Oncol. 2015 Oct 13. pii: S1368-8375(15)00331.
    PubMed     Text format     Abstract available


    September 2015
  184. RAMQVIST T, Mints M, Tertipis N, Nasman A, et al
    Studies on human papillomavirus (HPV) 16 E2, E5 and E7 mRNA in HPV-positive tonsillar and base of tongue cancer in relation to clinical outcome and immunological parameters.
    Oral Oncol. 2015 Sep 25. pii: S1368-8375(15)00327.
    PubMed     Text format     Abstract available


    July 2015
  185. LIU SZ, Zandberg DP, Schumaker LM, Papadimitriou JC, et al
    Correlation of p16 expression and HPV type with survival in oropharyngeal squamous cell cancer.
    Oral Oncol. 2015 Jul 13. pii: S1368-8375(15)00263.
    PubMed     Text format     Abstract available


    June 2015
  186. DAHLSTROM KR, Bell D, Hanby D, Li G, et al
    Socioeconomic characteristics of patients with oropharyngeal carcinoma according to tumor HPV status, patient smoking status, and sexual behavior.
    Oral Oncol. 2015 Jun 25. pii: S1368-8375(15)00239.
    PubMed     Text format     Abstract available


  187. ANDERSON KS, Gerber JE, D'Souza G, Pai SI, et al
    Biologic predictors of serologic responses to HPV in oropharyngeal cancer: The HOTSPOT study.
    Oral Oncol. 2015 Jun 18. pii: S1368-8375(15)00229.
    PubMed     Text format     Abstract available


  188. DUAN H, Gamper E, Becherer A, Hoffmann M, et al
    Quality of life aspects in the management of thyroid cancer.
    Oral Oncol. 2015;51:S1-5.
    PubMed     Text format     Abstract available


  189. DAN TD, Raben D, Schneider CJ, Hockstein NG, et al
    Freedom from local and regional failure of contralateral neck with ipsilateral neck radiotherapy for node-positive tonsil cancer: updated results of an institutional clinical management approach.
    Oral Oncol. 2015;51:616-21.
    PubMed     Text format     Abstract available


  190. JOSEPH LJ, Goodman M, Higgins K, Pilai R, et al
    Racial disparities in squamous cell carcinoma of the oral tongue among women: a SEER data analysis.
    Oral Oncol. 2015;51:586-92.
    PubMed     Text format     Abstract available


  191. MASON M, Giuliani M, Huang SH, Xu W, et al
    Extra-pulmonary small cell carcinoma in the head and neck setting: the role of prophylactic cranial irradiation.
    Oral Oncol. 2015;51:e57-9.
    PubMed     Text format     Abstract available


  192. ZHANG H, Dziegielewski PT, Jean Nguyen TT, Jeffery CC, et al
    The effects of geography on survival in patients with oral cavity squamous cell carcinoma.
    Oral Oncol. 2015;51:578-85.
    PubMed     Text format     Abstract available


  193. HUANG AT, Tang C, Bell D, Yener M, et al
    Prognostic factors in adenocarcinoma of the salivary glands.
    Oral Oncol. 2015;51:610-5.
    PubMed     Text format     Abstract available


    May 2015
  194. ANDERSON KS, Dahlstrom KR, Cheng JN, Alam R, et al
    HPV16 antibodies as risk factors for oropharyngeal cancer and their association with tumor HPV and smoking status.
    Oral Oncol. 2015 May 6. pii: S1368-8375(15)00186.
    PubMed     Text format     Abstract available


  195. ZEIDAN YH, Pekelis L, An Y, Holsinger FC, et al
    Survival benefit for adjuvant radiation therapy in minor salivary gland cancers.
    Oral Oncol. 2015;51:438-45.
    PubMed     Text format     Abstract available


  196. SINHA P, Kallogjeri D, Gay H, Thorstad WL, et al
    High metastatic node number, not extracapsular spread or N-classification is a node-related prognosticator in transorally-resected, neck-dissected p16-positive oropharynx cancer.
    Oral Oncol. 2015;51:514-20.
    PubMed     Text format     Abstract available


  197. CHEN TC, Wu CT, Wang CP, Yang TL, et al
    Significance of nuclear p-mTOR expression in advanced oral squamous cell carcinoma with extracapsular extension of lymph node metastases.
    Oral Oncol. 2015;51:493-9.
    PubMed     Text format     Abstract available


  198. XUELEI M, Jingwen H, Wei D, Hongyu Z, et al
    ERCC1 plays an important role in predicting survival outcomes and treatment response for patients with HNSCC: a meta-analysis.
    Oral Oncol. 2015;51:483-92.
    PubMed     Text format     Abstract available


  199. ANDERSON CR, Sisson K, Moncrieff M
    A meta-analysis of margin size and local recurrence in oral squamous cell carcinoma.
    Oral Oncol. 2015;51:464-9.
    PubMed     Text format     Abstract available


  200. DENG J, Ridner SH, Aulino JM, Murphy BA, et al
    Assessment and measurement of head and neck lymphedema: state-of-the-science and future directions.
    Oral Oncol. 2015;51:431-7.
    PubMed     Text format     Abstract available


  201. JEGU J, Belot A, Borel C, Daubisse-Marliac L, et al
    Effect of previous history of cancer on survival of patients with a second cancer of the head and neck.
    Oral Oncol. 2015;51:457-63.
    PubMed     Text format     Abstract available


    April 2015
  202. LEVY A, Leboulleux S, Lepoutre-Lussey C, Baudin E, et al
    (18)F-fluorodeoxyglucose positron emission tomography to assess response after radiation therapy in anaplastic thyroid cancer.
    Oral Oncol. 2015;51:370-5.
    PubMed     Text format     Abstract available


  203. JIMENO A, Bauman JE, Weissman C, Adkins D, et al
    A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer.
    Oral Oncol. 2015;51:383-8.
    PubMed     Text format     Abstract available


  204. MALI SB
    Stereotactic radiotherapy for head neck cancer.
    Oral Oncol. 2015;51:e19-20.
    PubMed     Text format    


  205. WANG W, Lim WK, Leong HS, Chong FT, et al
    An eleven gene molecular signature for extra-capsular spread in oral squamous cell carcinoma serves as a prognosticator of outcome in patients without nodal metastases.
    Oral Oncol. 2015;51:355-62.
    PubMed     Text format     Abstract available


    February 2015
  206. ETTL T, Viale-Bouroncle S, Hautmann MG, Gosau M, et al
    AKT and MET signalling mediates antiapoptotic radioresistance in head neck cancer cell lines.
    Oral Oncol. 2015;51:158-63.
    PubMed     Text format     Abstract available


  207. MOCHIZUKI Y, Harada H, Ikuta M, Shimamoto H, et al
    Clinical characteristics of multiple primary carcinomas of the oral cavity.
    Oral Oncol. 2015;51:182-9.
    PubMed     Text format     Abstract available


  208. OHMAN J, Rexius H, Mjornstedt L, Gonzalez H, et al
    Oral and lip cancer in solid organ transplant patients--a cohort study from a Swedish Transplant Centre.
    Oral Oncol. 2015;51:146-50.
    PubMed     Text format     Abstract available


  209. TSAI WC, Kung PT, Wang ST, Huang KH, et al
    Beneficial impact of multidisciplinary team management on the survival in different stages of oral cavity cancer patients: results of a nationwide cohort study in Taiwan.
    Oral Oncol. 2015;51:105-11.
    PubMed     Text format     Abstract available


  210. GOMES CC, Fonseca-Silva T, Galvao CF, Friedman E, et al
    Inter- and intra-lesional molecular heterogeneity of oral leukoplakia.
    Oral Oncol. 2015;51:178-81.
    PubMed     Text format     Abstract available


  211. FOTOPOULOS G, Pavlidis N
    The role of human papilloma virus and p16 in occult primary of the head and neck: a comprehensive review of the literature.
    Oral Oncol. 2015;51:119-23.
    PubMed     Text format     Abstract available


  212. MALI SB
    Proton therapy for head neck cancer.
    Oral Oncol. 2015;51:e10-2.
    PubMed     Text format    


  213. TANG C, Fuller CD, Garden AS, Awan MJ, et al
    Characteristics and kinetics of cervical lymph node regression after radiation therapy for human papillomavirus-associated oropharyngeal carcinoma: quantitative image analysis of post-radiotherapy response.
    Oral Oncol. 2015;51:195-201.
    PubMed     Text format     Abstract available


  214. YANG CN, Deng YT, Tang JY, Cheng SJ, et al
    MicroRNA-29b regulates migration in oral squamous cell carcinoma and its clinical significance.
    Oral Oncol. 2015;51:170-7.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Head and Neck Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: